It inhibits F‐box protein 31 (FBXO31), reducing ubiquitin‐mediated degradation of forkhead box M1 (FOXM1), ultimately leading to tumor progression and increased sorafenib resistance [245]. Here, FOXM1 is linked to neoplasm.